Search

Your search keyword '"Kannan, Meena A."' showing total 20 results
Start Over Author "Kannan, Meena A." Language english
20 results on '"Kannan, Meena A."'

1. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial

Author

Bourdette, Dennis, Yadav, Vijayshree, Goodman, Andrew, Racke, Michael, Fallis, Robert, Tornatore, Carlo, Goldman, Myla, Kannan, Meena, Sriram, Subramaniam, Berger, Joseph, Cross, Anne, Rammohan, Kottil, Xia, Zongqi, Leist, Thomas, Lynch, Sharon, Klawiter, Eric, Amezcua, Lilyana, Bowen, James, Corboy, John R, Fox, Robert J, Kister, Ilya, Cutter, Gary R, Morgan, Charity J, Seale, Rebecca, Engebretson, Eric, Gustafson, Tarah, and Miller, Aaron E

Published
2023
Full Text
View/download PDF

2. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

Author

van der Walt, Anneke, Dwyer, Christopher, Buzzard, Katherine, Spies, Judith, Parratt, John, van Pesch, Vincent, Willekens, Barbara, Perrotta, Gaetano, Bartholomé, Emmanuel, Grand'Maison, Francois, Jacques, Francois, Giacomini, Paul, Vosoughi, Reza, Girard, Jean-Marc, de Seze, Jerome, Lebrun Frenay, Christine, Ruet, Aurelie, Laplaud, David-Axel, Reifschneider, Gerd, Wagner, Bert, Rauer, Sebastian, Pul, Refik, Seipelt, Maria, Berthele, Achim, Klotz, Luisa, Kallmann, Boris-Alexander, Paul, Friedemann, Achiron, Anat, Lus, Giacomo, Centonze, Diego, Patti, Francesco, Grimaldi, Luigi, Hupperts, Raymond, Frequin, Stephan, Fermont, Jiske, Madueno, Sara Eichau, Alonso Torres, Ana Maria, Costa-Frossard França, Lucienne, Meca-Lallana, Jose Eustasio, Ruiz, Luis Brieva, Pearson, Owen, Rog, David, Evangelou, Nikolaos, Ismail, Azza, Lathi, Ellen, Fox, Edward, Leist, Thomas, Sloane, Jacob, Wu, Gregory, Khatri, Bhupendra, Steingo, Brian, Thrower, Ben, Gudesblatt, Mark, Calkwood, Jonathan, Bandari, Daniel, Scagnelli, John, Laganke, Christopher, Robertson, Derrick, Kipp, Lucas, Belkin, Martin, Cohan, Stanley, Goldstick, Lawrence, Courtney, Ardith, Vargas, Wendy, Sylvester, Andrew, Srinivasan, Jayshri, Kannan, Meena, Picone, Maryann, English, Jeffrey, Napoli, Salvatore, Balabanov, Roumen, Zaydan, Islam, Nicholas, Jacqueline, Kaplan, Jeffrey, Lublin, Fred, Riser, Emily, Miller, Tamara, Alvarez, Enrique, Wray, Sibyl, Gross, Jeffrey, Pawate, Siddharama, Hersh, Carrie, McCarthy, Lucas, Crayton, Heidi, Graves, Jennifer, Foley, John F, Defer, Gilles, Ryerson, Lana Zhovtis, Cohen, Jeffrey A, Arnold, Douglas L, Butzkueven, Helmut, Cutter, Gary, Giovannoni, Gavin, Killestein, Joep, Wiendl, Heinz, Smirnakis, Karen, Xiao, Shan, Kong, George, Kuhelj, Robert, and Campbell, Nolan

Published
2022
Full Text
View/download PDF

3. DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trial.

Author

Corboy, John R, Fox, Robert J, Cutter, Gary, Engebretson, Eric, Miller, Aaron, Morgan, Charity, Gustafson, Tarah, Goodman, Andrew D, Kannan, Meena, Sriram, Subramanian, Xia, Zongqi, Lynch, Sharon, Bowen, James, and Kister, Ilya

Subjects
MAGNETIC resonance imaging, BRAIN damage, LOG-rank test, MULTIPLE sclerosis, CLINICAL trials
Abstract

Background: In the DISCOMS (DISCOntinuation of disease-modifying therapies (DMTs) in multiple sclerosis (MS)) randomized clinical trial, we could not demonstrate that discontinuing MS DMTs in older, stable adults was not inferior to continuing DMTs. Relapses were rare in both groups, and most new disease activity was one to two new brain magnetic resonance imaging (MRI) lesions unassociated with clinical changes. Objective/Aims: Describe results of the DISCOMS extension study. Methods: Among 10/19 of the original sites, we enrolled patients who completed DISCOMS; did not reach the primary endpoint during the original trial; and retained original randomized assignment. Participants completed one study visit and brain MRI at least 30 months after original enrollment in DISCOMS. Primary endpoint was time from entry into the primary study to relapse or new brain MRI activity. Results: Mean (SD) total follow-up was 40 (11.7) months. There were no relapses, and new brain MRI lesions (1/30 continuer, 2/44 discontinuers) were uncommon during the extension. Time from primary trial entry to disease event was significantly shorter for subjects in the discontinue group (p = 0.043 from log-rank test). Conclusions: From entry into DISCOMS extension study, time to new MS activity remained shorter in discontinuers, but relapses were absent and new brain MRI lesions were rare. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

9. Congenital muscular dystrophy with inflammation: Diagnostic considerations

Author

Konkay, Kaumudi, Kannan, Meena, Lingappa, Lokesh, Uppin, Megha, and Challa, Sundaram

Subjects
Care and treatment, Analysis, Genetic aspects, Research, Risk factors, Muscular dystrophy -- Genetic aspects -- Research -- Risk factors -- Care and treatment, Inflammation -- Analysis -- Risk factors -- Care and treatment, Immunohistochemistry -- Analysis, Genetic disorders -- Analysis
Published
2016

14. Malignant infiltration of peripheral nerves: As initial presenting manifestation of lymphoreticular malignancies

Author

Kannan, Meena, Uppin, Megha, Jabeen, Sheik, Mridula, Rukmini, Challa, Sundaram, and Borgohain, Rupam

Subjects
Diagnosis, Case studies, Health aspects, Peripheral nerves -- Health aspects, Lymphomas -- Case studies -- Diagnosis, Neurologic manifestations -- Case studies -- Diagnosis, Nerves, Peripheral -- Health aspects, Neurologic manifestations of general diseases -- Case studies -- Diagnosis
Published
2014

15. Incidence of malignancies in biopsy-proven inflammatory myopathy

Author

Kannan, Meena, Sundaram, C., Uppin, Megha, Mridula, Rukmini, Jabeen, Sheik, and Borgohain, Rupam

Subjects
Diagnosis, Care and treatment, Research, Risk factors, Cancer -- Risk factors -- Research, Muscular diseases -- Diagnosis -- Care and treatment -- Research, Muscle diseases -- Diagnosis -- Care and treatment -- Research
Published
2013

16. Distal myopathy with rimmed vacuoles and inflammation: A genetically proven case

Author

Kannan, Meena, Challa, S., Urtizberea, Andoni, Krahn, Martin, Jabeen, A., and Borgohain, R.

Subjects
Diagnosis, Care and treatment, Genetic aspects, Case studies, Risk factors, Patient outcomes, Health aspects, Muscular dystrophy -- Genetic aspects -- Risk factors -- Diagnosis -- Care and treatment -- Patient outcomes -- Case studies, Gene mutation -- Health aspects, Gene mutations -- Health aspects
Published
2012

19. Incidence of malignancies in biopsy-proven inflammatory myopathy.

Author

Sundaram, C., Kannan, Meena A., Uppin, Megha, Mridula, Rukmini, Borgohain, Rupam, and Jabeen, Sheik Afshan

Subjects
*MUSCLE diseases, *DERMATOMYOSITIS, *MYOSITIS, *UNIVERSITY hospitals
Abstract

Background: Inflammatory myopathy (IM) as a manifestation of paraneoplastic syndrome has been well-documented. However, the prevalence of malignancies reported varies across the studies. There are very few studies reported from Asia, only one from India. Aim: The aim of this analysis was to study the prevalence of malignancy in biopsy-proven cases of IM in India and to study the difference between malignant and non-malignant groups. Materials and Methods: The study was a retrospective review of case records of patients with a biopsy-proven IM attending Tertiary Care University Hospital. Results: Of the total 86 patients with biopsy-proven IM, 22 patients were polymyositis, 63 patients had dermatomyositis (DM) and one was with an inclusion body myositis, not included for further analysis. Associated malignancy was diagnosed in 6 (7%) patients, and five of them were females. Diagnosis of associated malignancy was identified at the time of diagnosis of IM in four (66.7%) patients. All the six patients with an associated malignancy had DM. Only one patient died within 1 year of diagnosis. Creatinine kinase was much lower in patients with malignancy associated IM than in patients with no malignancy (P < 0.0001). Conclusion: The prevalence of malignancy was very low in our cohort as compared to the studies from other countries. Breast cancer was the most common malignancy associated with DM. The type of associated malignancy was quite variable. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

20. An ethical issue at follow-up.

Author

Kannan, Meena A.

Subjects
*NEUROPATHY, *GLUCOSE intolerance, *ELECTROPHYSIOLOGY
Abstract

A response by Meena A. Kannan to a letter to the editor about her article "Prevalence of Neuropathy in Patients With Impaired Glucose Tolerance Using Various Electrophysiological Tests" published in a 2014 issue is presented.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results